IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan-Prednisone Versus Melphalan-Prednisone in Newly Diagnosed Multiple Myeloma
Miguel, Jesus F. San1; Schlag, Rudolf2; Khuageva, Nuriet K.3; Dimopoulos, Meletios A.4; Shpilberg, Ofer5; Kropff, Martin H.6; Spicka, Ivan7; Petrucci, Maria Teresa8; Palumbo, Antonio9; Samoilova, Olga S.10; Dmoszynska, Anna11; Abdulkadyrov, Kudrat M.12; Schots, Rik13; Jiang, Bin14; Mateos, Maria-Victoria15; Anderson, Kenneth C.16; Esseltine, Dixie-Lee17; Liu, Kevin18; Cakana, Andrew19; van de Velde, Helgi19; Richardson, Paul
刊名BLOOD
2008-11-16
112期:11页:242-242
收录类别SCI
文章类型Meeting Abstract
WOS标题词Science & Technology
类目[WOS]Hematology
研究领域[WOS]Hematology
语种英语
WOS记录号WOS:000262104700651
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/58924
专题北京大学第二临床医学院
作者单位1.St Petersburg Clin Res Inst Hematol & Transfusiol, St Petersburg, Russia
2.Belgian Hematol Soc, Myeloma Study Grp, Brussels, Belgium
3.Peking Univ, Peoples Hosp, Beijing, Peoples R China
4.Hosp Univ Salamanca, Salamanca, Spain
5.Praxis Hematol & Oncol, Wurzburg, Germany
6.SP Botkin Moscow City Clin Hosp, Dept Hematol, Moscow, Russia
7.Rabin Med Ctr, Petah Tiqwa, Israel
8.Univ Munster, Munster, Germany
9.Charles Univ Praha, Dept Int Med 1, Prague, Czech Republic
10.Univ Roma La Sapienza, Rome, Italy
11.Med Univ Lublin, Lublin, Poland
12.Univ Turin, Div Ematol, AOU San Giovanni Battista, Turin, Italy
13.Nizhnii Novgorod Reg Clin Hosp, Nizhnii Novgorod, Russia
14.USAL, CSIC, IBMCC, CIC,Hosp Univ Salamanca, Salamanca, Spain
15.Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece
16.Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Dis Ctr, Boston, MA 02115 USA
17.Takeda Oncol Co, Millennium Pharmaceut, Cambridge, MA USA
18.Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA
19.Johnson & Johnson Pharmaceut Res & Dev, Dept Clin R&D Oncol, Beerse, Belgium
推荐引用方式
GB/T 7714
Miguel, Jesus F. San,Schlag, Rudolf,Khuageva, Nuriet K.,et al. Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan-Prednisone Versus Melphalan-Prednisone in Newly Diagnosed Multiple Myeloma[J]. BLOOD,2008,112(11):242-242.
APA Miguel, Jesus F. San.,Schlag, Rudolf.,Khuageva, Nuriet K..,Dimopoulos, Meletios A..,Shpilberg, Ofer.,...&Richardson, Paul.(2008).Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan-Prednisone Versus Melphalan-Prednisone in Newly Diagnosed Multiple Myeloma.BLOOD,112(11),242-242.
MLA Miguel, Jesus F. San,et al."Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan-Prednisone Versus Melphalan-Prednisone in Newly Diagnosed Multiple Myeloma".BLOOD 112.11(2008):242-242.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Miguel, Jesus F. San]的文章
[Schlag, Rudolf]的文章
[Khuageva, Nuriet K.]的文章
百度学术
百度学术中相似的文章
[Miguel, Jesus F. San]的文章
[Schlag, Rudolf]的文章
[Khuageva, Nuriet K.]的文章
必应学术
必应学术中相似的文章
[Miguel, Jesus F. San]的文章
[Schlag, Rudolf]的文章
[Khuageva, Nuriet K.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。